# KYNTRA BIO, INC. (KYNB) · Edgar & Edgarette company card

> Kyntra Bio (KYNB) saw revenue fall 78.3% in FY2025 to $6 million, operating margin -713% against a -3.8% median for pharmaceutical preparations, equity -25.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 921299 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/KYNB) · [JSON](https://www.pops4.com/boards/company/KYNB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $6M |
| Revenue growth, 1 year | -78.3% |
| Revenue growth per year | -59.3% |
| Operating margin | -712.7% (prior year -507.8%) |
| Net margin | 2848.6% |
| Operating cash flow | −$5M |
| Capital spending | $38,000 |
| Free cash flow | −$5M |
| Cash | $48M |
| Long-term debt | — |
| Total assets | $120M |
| Total equity | −$30M |
| Equity ÷ assets | -25.1% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -45.53 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -712.7% in FY2025; revenue is hard to predict: its 80% range is ±68%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $6.4M (FY2025). Experience: revenue down 78.3% on the year, down 59.3% a year over 4 years; operating margin -712.7%, down from -507.8%. Soundness: equity -25.1% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $800K and $4.2M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $715K to $4.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -712.7% against a -3.8% median; growth -78.3% against 13.7%.

Range logged 2026-10-02, receipt 5786e2739b36c343, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-10-06 ([filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/0001193125-26-415545-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-10-01 ([filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm))

## Recent filings

- 8-K · filed 2026-10-06 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/0001193125-26-415545-index.htm)
- 8-K · filed 2026-10-01 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526409819/0001193125-26-409819-index.htm)
- 8-K · filed 2026-08-31 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/0001193125-26-377059-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526349183/0001193125-26-349183-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526349141/0001193125-26-349141-index.htm)
- 8-K · filed 2026-06-16 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/0001193125-26-271449-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000921299.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=921299

## Cite

POPS4, Edgar & Edgarette: KYNTRA BIO, INC. (KYNB) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/KYNB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

